Compare Regeneron Pharmaceuticals Inc (REGN) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Workiva Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Workiva Inc trades at $52.5 (market cap $3.08B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 23× Workiva Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| REGN | WK | |
|---|---|---|
Market Cap | $70.79B | $3.08B |
Sector | Health | Technology |
52-Week High | $812.27 | $93.31 |
52-Week Low | $545.46 | $44.31 |
Enterprise Value | $64.74B | $3.01B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Workiva (WK) trades at $57.19, up 0.02% on the day, with a bullish technical outlook from moving averages and strong analyst support. The company shows robust revenue growth, reaching $884.57M in 2025, and has consistently beaten earnings estimates in recent quarters. Recent news highlights its AI-powered platform growth and upcoming Q2 2026 results.
The stock presents a positive outlook with an 88.89% buy rating from analysts and a consensus price target of $71.00, suggesting 24% upside. Risks include high valuation multiples (P/E 238.29) and profitability challenges, with net income margin at 1.53% for 2026. Investors should weigh growth potential against execution risks in a competitive software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
